Jobs / United States / Glaxosmithkline LLC
NPI Portfolio and Transformation Lead
Glaxosmithkline LLC · 🇺🇸 USA - North Carolina - Zebulon
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
The purpose of this role is to lead delivery of the site transformation strategy established by the Site Leadership Team (SLT), while providing analysis, options, feasibility assessments and recommendations to support strategy development. The role translates approved priorities into integrated, executable programs and is accountable for delivery of the site-wide transformation portfolio, the New Product Introduction (NPI) portfolio, technical transfers and key strategic initiatives designated by the SLT. The role leads cross-functional delivery across Manufacturing, Quality, MSAT, Engineering, Supply Chain, Regulatory, CMC and other relevant functions; establishes fit-for-purpose governance; manages dependencies, resources, risks and decisions; and ensures agreed outcomes and benefits are achieved through implementation, stabilization and formal handover. Functional leaders retain technical approval, compliance and sustained operational accountability within their respective area. • Translate the site transformation strategy and SLT-approved priorities into an integrated portfolio roadmap, providing data, options, feasibility assessments, sequencing recommendations, resource requirements and delivery risks to support SLT decision-making. • Lead end-to-end delivery of the site transformation portfolio, NPI portfolio, technical transfers and key strategic initiatives designated by the SLT, ensuring alignment to approved scope, milestones, business objectives and measurable benefits. • Establish and lead fit-for-purpose governance for portfolio projects and designated strategic initiatives, including prioritization, stage gates, integrated plans, performance reporting, risk and issue management, decision tracking and timely escalation. This remit does not extend to routine functional projects or constitute ownership of a general site PMO; functional leaders remain accountable for projects within their normal operational remit. • Provide direct leadership to the permanent NPI team and delivery leadership to cross-functional resources assigned to transformation initiatives. Ensure the organization is appropriately structured, resourced and developed, while assigned resources retain their normal functional reporting lines and accountabilities. • Lead integrated delivery planning for regulatory submissions, process validation, technology transfer, operational readiness and inspection readiness. Ensure Quality, Regulatory, MSAT, Engineering, Manufacturing and Supply Chain owners have aligned plans, dependencies, milestones and risk mitigations, while functional experts retain technical approval and compliance accountability. • Ensure capital projects supporting NPI, transformation and operational readiness are integrated into the overall portfolio plan, with aligned scope, milestones, dependencies, qualification requirements and risk mitigations. Engineering retains accountability for capital-project execution, technical decisions and applicable engineering standards. • Ensure operational readiness across people, process, plant, materials, systems and ways of working, including training, procedures, supply continuity, equipment and facility readiness, and effective transition into routine operations. • Drive continuous improvement and sustainable change across the approved portfolio, establishing balanced success measures including on-time delivery, milestone performance, benefits realization, operational readiness, quality and Right First Time, cost performance and risk reduction. • Ensure portfolio projects and strategic initiatives deliver approved objectives and measurable benefits through implementation and stabilization; confirm required controls and capabilities are embedded and complete formal handover to the accountable